Xuanzhu Biopharmaceutical Co (HKSE:02575) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02575 Xuanzhu Biopharmaceutical Co Ltd HKSE:02575
11 GF Score
Price HK$12.88
! 1 Warning Sign
View Full Analysis

What is Xuanzhu Biopharmaceutical Co LT-Debt-to-Total-Asset?

Xuanzhu Biopharmaceutical Co HKSE:02575 11 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates HKSE:02575 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Xuanzhu Biopharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Xuanzhu Biopharmaceutical Co's long-term debt to total assets ratio declined from Dec. 2024 (0.00) to Dec. 2025 (0.00). It may suggest that Xuanzhu Biopharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Xuanzhu Biopharmaceutical Co  (HKSE:02575) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Xuanzhu Biopharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Xuanzhu Biopharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Xuanzhu Biopharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xuanzhu Biopharmaceutical Co LT-Debt-to-Total-Asset Chart

Xuanzhu Biopharmaceutical Co Annual Data
Trend Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.01 0.00 0.00

Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset 0.01 0.00 0.00 0.00 0.00
HKSE:02575
11GF Score
Xuanzhu Biopharmaceutical Co Ltd HKSE:02575
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xuanzhu Biopharmaceutical Co LT-Debt-to-Total-Asset Calculation

Xuanzhu Biopharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/1812.13
=0.00

Xuanzhu Biopharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0/1812.13
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Xuanzhu Biopharmaceutical Co and its competitors.
Is Xuanzhu Biopharmaceutical Co's LT-Debt-to-Total-Asset too high?
Xuanzhu Biopharmaceutical Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's LT-Debt-to-Total-Asset compare to ZTS?
Xuanzhu Biopharmaceutical Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. Xuanzhu Biopharmaceutical Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xuanzhu Biopharmaceutical Co Business Description

Address Zhubang 2000 Business Center, 2107, Building 2, Balizhuang Xili, Chaoyang District, Beijing, CHN
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score

Get the complete analysis for HKSE:02575

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$12.88
Price